14-3-3 Proteins Linked to Therapy Resistance in Digestive Cancers
The review identifies specific 14-3-3-client modules that contribute to therapy resistance in gastric, colorectal, pancreatic, and hepatobiliary cancers.
Phase III
gastric cancer treatments
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The identification of 14-3-3-client modules linked to therapy resistance in digestive cancers is critical for enhancing treatment efficacy. Pharma strategy teams should explore these mechanisms to inform drug development and improve patient outcomes in oncology.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor ongoing research on 14-3-3 protein inhibitors and their clinical trials in digestive cancers.
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.